Retrospective Evaluation of CML Patients in the National Compassionate Program

Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree

This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.

This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.

Inclusion Criteria:

• CML Ph+ patients in chronic phase
• 18 years old or older
• Patients have received either Dasatinib or Nilotinib and resulted resistant or not tolerant to the drugs or have developed the T3151 mutation
• Patients have started Ponatinib at least 12 months before registration
• Informed consent signed at registration

Exclusion Criteria:

• CML Ph+ patients in accelerated or blast phase with acute lymphoblastic leukemia